Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Zhao, Miao ^a   Bai, Yu ^a   Liu, Wei ^a   Xiao, Xiangqian ^a   Huang, Yuming ^c   Cen, Shan ^d   Chan, Paul Ks ^e   Sun, Xin ^b   Sheng, Wang ^a   Zeng, Yi ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^b BEIHUA UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chimeric virus like particle; Enterovirus 71; Peptide; Vaccine; VP4

Indexed keywords

HEPATITIS B CORE ANTIGEN; PROTEIN VP4;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; ELECTRON MICROSCOPY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; ESCHERICHIA COLI; GENOTYPE; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MOUSE; NONHUMAN; VIRUS LIKE AGENT;

HUMAN ENTEROVIRUS 71; MUS;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; CROSS REACTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; FEMALE; HAND, FOOT AND MOUTH DISEASE; HEPATITIS B CORE ANTIGENS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84889873100     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-287     Document Type: Article

References (42)

1. An Apparently New Enterovirus Isolated from Patients with Disease of the Central Nervous System. Schmidt NJ, Lennette EH, Ho HH, J Infect Dis 1974 129 3 304 309 10.1093/infdis/129.3.304 4361245
2. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Brown BA, Pallansch MA, Virus Res 1995 39 2-3 195 205 8837884 (Pubitemid 26054785)
3. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Chung Y-C, Ho M-S, Wu J-C, Chen W-J, Huang J-H, Chou S-T, Hu Y-C, Vaccine 2008 26 15 1855 1862 10.1016/j.vaccine.2008.01.058 18329759
4. Picornaviruses. Tuthill T, Groppelli E, Hogle J, Rowlands D, Cell Entry by Non-Enveloped Viruses Germany: Springer Berlin Heidelberg, Johnson JE, 343 2010 43 89
5. Myristylation of picornavirus capsid protein VP4 and its structural significance. Chow M, Newman JFE, Filman D, Hogle JM, Rowlands DJ, Brown F, Nature 1987 327 6122 482 486 10.1038/327482a0 3035380 (Pubitemid 17085817)
6. Antiviral agent blocks breathing of the common cold virus. Lewis JK, Bothner B, Smith TJ, Siuzdak G, Proc Natl Acad Sci 1998 95 12 6774 6778 10.1073/pnas.95.12.6774 9618488 (Pubitemid 28278056)
7. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, et al. Nat Struct Mol Biol 2012 19 4 424 429 10.1038/nsmb.2255 22388738
8. An overview of the evolution of enterovirus 71 and its clinical and public health significance. McMinn PC, FEMS Microbiol Rev 2002 26 1 91 107 10.1111/j.1574-6976.2002.tb00601.x 12007645 (Pubitemid 34454778)
9. Risk factors for severe hand foot and mouth disease. Suzuki Y, Taya K, Nakashima K, Ohyama T, Kobayashi JM, Ohkusa Y, Okabe N, Pediatr Int 2010 52 2 203 207 10.1111/j.1442-200X.2009.02937.x 19663940
10. Population Dynamics and Genetic Diversity of C4 Strains of Human Enterovirus 71 in Mainland China, 1998-2010. Guan D, van der Sanden S, Zeng H, Li W, Zheng H, Ma C, Su J, Liu Z, Guo X, Zhang X, et al. PLoS ONE 2012 7 9 44386 10.1371/journal.pone.0044386 22984501
11. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VTK, Int J Infect Dis 2010 14 12 1076 e1081 10.1016/j.ijid.2010.07.006 20952237
12. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E, Nakamura K, Tanaka Y, Endo K, Tanaka K, Ueda J, et al. Japanese journal of infectious diseases 2009 62 4 254 259 19628900
13. An Eight-Year Study of Epidemiologic Features of Enterovirus 71 Infection In Taiwan. Chen S-C, Chang H-L, Yan T-R, Cheng Y-T, Chen K-T, AmJTrop Med Hyg 2007 77 1 188 191 (Pubitemid 351844373)
14. Epidemiologic Features of Hand-Foot-Mouth Disease and Herpangina Caused by Enterovirus 71 in Taiwan, 1998-2005. Chen K-T, Chang H-L, Wang S-T, Cheng Y-T, Yang J-Y, Pediatrics 2007 120 2 244 e252 10.1542/peds.2006-3331 17671037 (Pubitemid 47219473)
15. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH, Lancet Infect Dis 2010 10 11 778 790 10.1016/S1473-3099(10)70194-8 20961813
16. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Liu C-C, Chou A-H, Lien S-P, Lin H-Y, Liu S-J, Chang J-Y, Guo M-S, Chow Y-H, Yang W-S, Chang KH-W, et al. Vaccine 2011 29 26 4362 4372 10.1016/j.vaccine.2011.04.010 21501643
17. Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Chang GH, Luo YJ, Wu XY, Si BY, Lin L, Zhu QY, Virology journal 2010 7 106 10.1186/1743-422X-7-106 20500892
18. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL, Virus Res 2007 125 1 61 68 10.1016/j.virusres.2006.12.005 17222936 (Pubitemid 46413387)
19. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Foo DG, Alonso S, Chow VT, Poh CL, Microbes and infection/Institut Pasteur 2007 9 11 1299 1306 10.1016/j.micinf.2007.06.002 (Pubitemid 47539204)
20. Combined peptides of human enterovirus 71 protect against virus infection in mice. Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF, et al. Vaccine 2010 28 46 7444 7451 10.1016/j.vaccine.2010.08.080 20831911
21. Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes. Yoke-Fun C, AbuBakar S, BMC microbiology 2006 6 74 10.1186/1471-2180-6-74 16939656 (Pubitemid 44408788)
22. Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Huang SW, Kiang D, Smith DJ, Wang JR, Experimental biology and medicine (Maywood, NJ) 2011 236 8 899 908 10.1258/ebm.2010.010233
23. An epidemic of enterovirus 71 infection in Taiwan. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR, Taiwan Enterovirus Epidemic Working Group. The New England journal of medicine 1999 341 13 929 935 (Pubitemid 29441546)
24. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, et al. Virology journal 2010 7 94 10.1186/1743-422X-7-94 20459851
25. Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. Zhang Y, Tan X, Cui A, Mao N, Xu S, Zhu Z, Zhou J, Shi J, Zhao Y, Wang X, et al. PLoS One 2013 8 2 56341 10.1371/journal.pone.0056341 23441179
26. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS, Vaccine 2001 20 5-6 895 904 11738755 (Pubitemid 34015831)
27. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC, Vaccine 2010 28 43 6951 6957 10.1016/j.vaccine.2010.08.052 20797455
28. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Tung WS, Bakar SA, Sekawi Z, Rosli R, Genetic vaccines and therapy 2007 5 6 10.1186/1479-0556-5-6 17445254
29. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Chiu CH, Chu C, He CC, Lin TY, Microbes and infection/Institut Pasteur 2006 8 7 1671 1678 10.1016/j.micinf.2006.01.021 (Pubitemid 44128870)
30. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H, Journal of virology 2007 81 17 9386 9395 10.1128/JVI.02856-06 17567701 (Pubitemid 47311481)
31. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Dong C, Wang J, Liu L, Zhao H, Shi H, Zhang Y, Jiang L, Li Q, Human vaccines 2010 6 12 1028 1037 10.4161/hv.6.12.12982 21150270
32. Study of the integrated immune response induced by an inactivated EV71 vaccine. Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, et al. PLoS One 2013 8 1 54451 10.1371/journal.pone.0054451 23372725
33. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, Na R, Liang Y, Wang L, Li Q, Vaccine 2011 29 37 6269 6275 10.1016/j.vaccine.2011.06.044 21722686
34. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC, Vaccine 2011 29 29-30 4829 4838 21550375
35. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA, Journal of virology 1999 73 12 9969 9975 10559310
36. An Immunodominant N-Terminal Region of VP1 Protein of Poliovirion That Is Buried in Crystal Structure Can Be Exposed in Solution. Roivainen M, Piirainen L, Ryä T, Närvänen A, Hovi T, Virology 1993 195 2 762 765 10.1006/viro.1993.1427 8393243
37. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. Li Q, Yafal AG, Lee YM, Hogle J, Chow M, J Virol 1994 68 6 3965 3970 7514682 (Pubitemid 24177422)
38. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ, Journal of virology 2009 83 14 7040 7048 10.1128/JVI.00557-09 19403680
39. Three-dimensional structure of poliovirus at 2.9 A resolution. Hogle J, Chow M, Filman D, Science 1985 229 4720 1358 1365 10.1126/science.2994218 2994218 (Pubitemid 16222374)
40. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. Fricks CE, Hogle JM, J Virol 1990 64 5 1934 1945 2157861 (Pubitemid 20148434)
41. Mechanisms of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. Greve JM, Forte CP, Marlor CW, Meyer AM, Hoover-Litty H, Wunderlich D, McClelland A, J Virol 1991 65 11 6015 6023 1681115
42. Recombinant VP4 of human rhinovirus induces permeability in model membranes. Davis MP, Bottley G, Beales LP, Killington RA, Rowlands DJ, Tuthill TJ, Journal of virology 2008 82 8 4169 4174 10.1128/JVI.01070-07 18256154 (Pubitemid 351521253)